相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Precision medicine oncology pharmacists have become essential members of multidisciplinary cancer care teams, contributing to targeted therapy selection, molecular tumor board discussions, and patient access to novel drug combinations. - These specialized pharmacists address significant barriers to precision oncology implementation, including complex medication access pathways, insurance restrictions, and the need for comprehensive patient education on oral anticancer medications. - Despite the expanding role of pharmacists in precision medicine, up to 70% remain unaware of institutional precision medicine initiatives, highlighting the need for increased training and institutional support to fully realize their potential in personalized cancer care.
- Two bispecific T-cell engagers, epcoritamab-bysp and glofitamab-gxbm, received FDA accelerated approval in 2023 for relapsed/refractory diffuse large B-cell lymphoma, offering new treatment options for heavily pretreated patients. - Both agents demonstrate remarkable activity with overall response rates above 50-60% and complete response rates around 40% in patients with CAR T-cell therapy failure, addressing a significant unmet medical need. - Epcoritamab offers convenient subcutaneous administration in outpatient settings with manageable cytokine release syndrome rates below 3%, while glofitamab provides fixed-duration therapy with durable responses lasting over one year after treatment completion. - These bispecific antibodies may challenge the paradigm that CAR T-cell therapy is the only curative option for relapsed/refractory patients, with emerging data suggesting potential for long-term disease control.
